Edgewise

Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024

Retrieved on: 
星期五, 五月 10, 2024
Health, Communications, Clinical Trials, Pharmaceutical, Cardiology, Biotechnology, Public Relations, Investor Relations, Therapy, Webcast, Edgewise, Conference

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 15, 2024, at 3:35 pm ET.

Key Points: 
  • Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the RBC Capital Markets Global Healthcare Conference on Wednesday, May 15, 2024, at 3:35 pm ET.
  • The presentation will be webcast live; a link for the webcast can be found on the Edgewise events page and will be accessible for replay following the presentation.
  • It is recommended that users connect to the webcast several minutes prior to the start to ensure a timely connection.

Edgewise Therapeutics Announces Upcoming Podium Presentation at the American College of Cardiology's 2024 Annual Scientific Session

Retrieved on: 
星期四, 三月 28, 2024
Biotechnology, Pharmaceutical, Health, Cardiology, Pharmacology, Congress Center, Edgewise, Patient, Heart, Heart failure, American College, HCM, Therapy, ACC, Cardiomyopathy, Pharmaceutical industry

Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the Company will present data on EDG-7500 at the American College of Cardiology's Annual Scientific Session (ACC.24).

Key Points: 
  • Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the Company will present data on EDG-7500 at the American College of Cardiology's Annual Scientific Session (ACC.24).
  • The conference will take place in Atlanta, GA at the Georgia World Congress Center from April 6-8, 2024.
  • “EDG-7500 is a novel investigational therapy for the treatment of HCM with a differentiated mechanism of action,” said Kevin Koch, Ph.D., President and Chief Executive Officer, Edgewise Therapeutics.
  • “Importantly, in our preclinical studies, EDG-7500 has shown potent gradient reduction, normalization of hyperdynamic contractility, and significant improvements in ventricular filling.

Edgewise Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium on April 2, 2024

Retrieved on: 
星期三, 三月 27, 2024
Biotechnology, Health, Pharmaceutical, Physical Therapy, Cardiology, Edgewise, Webcast, Therapy

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Cantor Virtual Muscular Dystrophy Symposium on Tuesday, April 2, 2024, at 2:20 pm ET.

Key Points: 
  • Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Cantor Virtual Muscular Dystrophy Symposium on Tuesday, April 2, 2024, at 2:20 pm ET.
  • The presentation will be webcast live; a link for the webcast can be found on the Edgewise events page and will be accessible for replay following the presentation.
  • It is recommended that users connect to the webcast several minutes prior to the start to ensure a timely connection.

Edgewise Therapeutics to Present at the Leerink Partners Global Biopharma Conference on March 11, 2024

Retrieved on: 
星期二, 三月 5, 2024
Biotechnology, Health, Pharmaceutical, Physical Therapy, Cardiology, Therapy, Webcast, Edgewise, Conference

Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Leerink Partners Global Biopharma Conference on Monday, March 11, 2024, at 12:00 pm ET.

Key Points: 
  • Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the Leerink Partners Global Biopharma Conference on Monday, March 11, 2024, at 12:00 pm ET.
  • The presentation will be webcast live; a link for the webcast can be found on the Edgewise events page and will be accessible for replay following the presentation.
  • It is recommended that users connect to the webcast several minutes prior to the start to ensure a timely connection.

Edgewise Therapeutics to Present on EDG-5506 for the Treatment of Becker Muscular Dystrophy at the 2024 MDA Clinical and Scientific Conference

Retrieved on: 
星期三, 二月 28, 2024
Biotechnology, Health, Pharmaceutical, Physical Therapy, Cardiology, BMD, Exercise, Principal investigator, Network, Myopathy, Edgewise, Conference, Muscular Dystrophy Association, University, Therapy, ARCH, Associate professor, University of Florida, Poster, Trade, Convention, MDA, Physiology, Episcopal conference, University of Copenhagen

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on EDG-5506, an investigational therapy designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies, at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference.

Key Points: 
  • Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the company will present data on EDG-5506, an investigational therapy designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies, at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference.
  • The conference will take place at the Hilton Orlando in Orlando, FL from March 3-6, 2024.
  • Posters will be showcased during the Networking & Poster Reception in the Exhibit Hall on Monday, March 4, 2024, from 6 – 8 PM ET.
  • The Edgewise presentation and posters will be available on the Edgewise website when they are presented.

Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock

Retrieved on: 
星期五, 一月 19, 2024
Biotechnology, Pharmaceutical, Health, Cardiology, Janus, Citadel, Myopathy, Patient, Therapy, Research, SVB Securities, OrbiMed, Edgewise, Prospectus, Novo Holdings A/S, Form, Sale, Becker muscular dystrophy, ATTN:, Montgomery Street, Attention, Telephone, State Street

Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a leading muscle disease biopharmaceutical company, today announced the pricing of an underwritten offering of 21,818,182 shares of its common stock at an offering price of $11.00 per share.

Key Points: 
  • Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a leading muscle disease biopharmaceutical company, today announced the pricing of an underwritten offering of 21,818,182 shares of its common stock at an offering price of $11.00 per share.
  • Edgewise anticipates gross proceeds from the offering to be approximately $240 million, before deducting underwriting discounts and commissions and offering expenses.
  • The closing of the offering is expected to occur on January 23, 2024, subject to the satisfaction of customary closing conditions.
  • A prospectus supplement and accompanying prospectus relating to the offering will also be filed with the SEC.

Edgewise Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on January 9, 2024

Retrieved on: 
星期二, 十二月 19, 2023
Biotechnology, Pharmaceutical, Health, Physical Therapy, Webcast, Conference, Edgewise, Therapy

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the J.P. Morgan 42nd Annual Healthcare Conference on Tuesday, January 9, 2024, at 10:30 am PT (1:30 pm ET).

Key Points: 
  • Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that management will present at the J.P. Morgan 42nd Annual Healthcare Conference on Tuesday, January 9, 2024, at 10:30 am PT (1:30 pm ET).
  • The presentation will be webcast live; a link for the webcast can be found on the Edgewise events page and will be accessible for replay following the presentation.
  • It is recommended that users connect to the webcast several minutes prior to the start to ensure a timely connection.

Edgewise Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights

Retrieved on: 
星期四, 十一月 9, 2023
Biotechnology, Health, Pharmaceutical, Physical Therapy, Cardiology, LYNX, Research, FOX, DUNE, Ageing, Education, Biomarker, Muscular dystrophy, Muscular Dystrophy Association, NSAA, G&A, Myopathy, Glycogen storage disease type V, American Heart Association, WMS, R, Muscle contraction, Pharmacokinetics, Dystrophinopathy, Disorder, Glycogen, PK, Clinical trial, Duchenne muscular dystrophy, McArdle, Safety, HCM, Therapy, Patient, MESA, R9, Administration, Pharmaceutical industry, Edgewise, Duchenne, Becker

Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the third quarter of 2023 and recent business highlights.

Key Points: 
  • Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today reported financial results for the third quarter of 2023 and recent business highlights.
  • “I’m thrilled with the progress we’ve made in 2023 across our skeletal and cardiovascular programs,” said Kevin Koch, Ph.D., President and Chief Executive Officer of Edgewise.
  • Research and development (R&D) expenses were $23.8 million for the third quarter of 2023, compared to $19.6 million for the immediately preceding quarter.
  • General and Administrative (G&A) expenses were $5.7 million for the third quarter of 2023, compared to $5.8 million for the immediately preceding quarter.

Edgewise Therapeutics to Present at Upcoming Investor Conferences

Retrieved on: 
星期三, 十一月 8, 2023
Health, Clinical Trials, Research, Science, Pharmaceutical, Cardiology, Biotechnology, Edgewise, Therapy, Pharmaceutical industry, Broadcasting

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, announced today that members of its senior management team will participate in the following upcoming investor conferences:

Key Points: 
  • Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, announced today that members of its senior management team will participate in the following upcoming investor conferences:
    The presentations will be webcast live; links for the webcasts can be found on the Edgewise events page and will be accessible for replay following the presentations.
  • It is recommended that users connect to the webcasts several minutes prior to the start to ensure a timely connection.

Edgewise to Present Data on EDG-7500 at the American Heart Association’s Scientific Sessions 2023

Retrieved on: 
星期三, 十一月 1, 2023
Health, Genetics, Research, Science, Pharmaceutical, Cardiology, Biotechnology, Heart failure, Intrinsic and extrinsic properties, Edgewise, Hypertrophic cardiomyopathy, Poster, American Heart, HCM, Therapy, AHA, Rapid Fire, Medical device, Vitro

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the Company will present the results of nonclinical studies of EDG-7500 at the American Heart Association’s (AHA) Scientific Sessions 2023 being held in Philadelphia from November 11 - 13.

Key Points: 
  • Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced that the Company will present the results of nonclinical studies of EDG-7500 at the American Heart Association’s (AHA) Scientific Sessions 2023 being held in Philadelphia from November 11 - 13.
  • EDG-7500 is a first-in-class oral, selective, cardiac sarcomere modulator, specifically designed to slow early contraction velocity and address impaired cardiac relaxation associated with hypertrophic cardiomyopathy (HCM) and other diseases of diastolic dysfunction.
  • Details of the Rapid Fire Oral Presentation:
    Title: EDG-7500, a Novel Cardiac Sarcomere Regulator That Preserves Intrinsic Myosin-Motor Function, Improves Cardiac Function and Reserve in a Minipig Model of Hypertrophic Cardiomyopathy
    Session: The Pharmacologic Management of Heart Failure: Beyond Guidelines and Paradigms
    Details of the Scientific Poster Presentation:
    Title: Cardiac Effects of EDG-7500, a Novel Cardiac Sarcomere Regulator: In Vitro and In Vivo Evidence for Slowing Isovolumic Contraction and Improved Ventricular Compliance (Board #2163)
    The AHA Scientific Sessions’ program is available here .
  • The Edgewise presentation and poster will be available on the Edgewise website when they are presented.